[{"orgOrder":0,"company":"Onxeo","sponsor":"Acrotech Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Belinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Onxeo","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Onxeo \/ Acrotech Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"Onxeo \/ Acrotech Biopharma"},{"orgOrder":0,"company":"University of Utah","sponsor":"Bristol Myers Squibb | Acrotech Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Belinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"University of Utah","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Utah \/ Bristol Myers Squibb | Acrotech Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"University of Utah \/ Bristol Myers Squibb | Acrotech Biopharma"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Belinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase III","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acrotech Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Acrotech Biopharma \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Belinostat

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : Belinostat is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lymphoma, T-Cell, Peripheral.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          October 10, 2023

                          Lead Product(s) : Belinostat

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          The Battery Show
                          Not Confirmed
                          The Battery Show
                          Not Confirmed

                          Details : The new Agreement grants Acrotech a royalty-free license to belinostat in all other territories including the United States, Canada, Mexico, and India.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : $6.6 million

                          April 06, 2020

                          Lead Product(s) : Belinostat

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Acrotech Biopharma

                          Deal Size : $6.6 million

                          Deal Type : Agreement

                          blank

                          03

                          University of Utah

                          Country arrow
                          The Battery Show
                          Not Confirmed

                          University of Utah

                          Country arrow
                          The Battery Show
                          Not Confirmed

                          Details : Belinostat is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Cytotoxic Drug

                          Upfront Cash : Inapplicable

                          March 19, 2020

                          Lead Product(s) : Belinostat

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Bristol Myers Squibb | Acrotech Biopharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank